학술논문
NS-001: Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia August 2022 22 Supplement:S195-S195
Subject
Language
ISSN
2152-2650